Aevice Health vs Umoja Biopharma
Side-by-side comparison of AI visibility scores, market position, and capabilities
Aevice Health raised $30M Series B in 2025 for its AI-powered wearable respiratory monitor that continuously tracks wheezing, coughing, and breathing abnormalities in asthma and COPD patients.
About
Aevice Health develops wearable respiratory monitoring technology that uses AI to analyze breath sounds captured continuously from a chest-worn device. The AeviceMD system detects wheezing, coughing, and abnormal breathing patterns in real time, enabling early warning of asthma attacks and COPD exacerbations before they require emergency care. The device transmits data to a smartphone app and clinical dashboard for remote monitoring by pulmonologists.
Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing.
About
Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.